Company registration number 04771472 (England and Wales)
PARKSIDE PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
PARKSIDE PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
PARKSIDE PHARMACY LIMITED
BALANCE SHEET
AS AT
30 JUNE 2025
30 June 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
-
0
-
0
Tangible assets
5
138,245
174,777
Current assets
Stocks
50,682
47,656
Debtors
6
1,348,592
1,195,462
Cash at bank and in hand
118,655
102,350
1,517,929
1,345,468
Creditors: amounts falling due within one year
7
(447,294)
(401,448)
Net current assets
1,070,635
944,020
Total assets less current liabilities
1,208,880
1,118,797
Creditors: amounts falling due after more than one year
8
(92,208)
(131,048)
Provisions for liabilities
(9,550)
(23,133)
Net assets
1,107,122
964,616
Capital and reserves
Called up share capital
2
2
Profit and loss reserves
1,107,120
964,614
Total equity
1,107,122
964,616
PARKSIDE PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 JUNE 2025
30 June 2025
- 2 -

For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 29 January 2026 and are signed on its behalf by:
Mr S Nair
Director
Company registration number 04771472 (England and Wales)
PARKSIDE PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 3 -
1
Accounting policies
Company information

Parkside Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is Front Street, Bellingham, Hexham, Northumberland, NE48 2AA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.

Parkside Pharmacy Limited is a wholly owned subsidiary of Parkside Pharmacare Limited.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is twenty years, this is longer than the recommended ten years however is deemed a more accurate life time.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
2% Straight line
Plant and equipment
15% Reducing balance
Computers
3 years Straight line
Motor vehicles
20% Straight line
PARKSIDE PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

PARKSIDE PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

PARKSIDE PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 6 -

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
11
20
4
Intangible fixed assets
Goodwill
£
Cost
At 1 July 2024 and 30 June 2025
200,000
Amortisation and impairment
At 1 July 2024 and 30 June 2025
200,000
Carrying amount
At 30 June 2025
-
0
At 30 June 2024
-
0

Goodwill is written off over 20 years, which is longer than the recommended 10 years, however due to strong demand and a limited supply of retail pharmacies, this is deemed a more accurate assessment of the useful life. Goodwill is now nearly fully utilised so any changes in the useful life will not have a material effect on the annual amortisation charge.

PARKSIDE PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 7 -
5
Tangible fixed assets
Freehold land and buildings
Plant and equipment
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 July 2024
100,527
57,869
1,382
128,509
288,287
Additions
-
0
1,450
-
0
-
0
1,450
Disposals
-
0
-
0
-
0
(45,405)
(45,405)
At 30 June 2025
100,527
59,319
1,382
83,104
244,332
Depreciation and impairment
At 1 July 2024
18,283
51,893
845
42,489
113,510
Depreciation charged in the year
2,011
951
461
26,235
29,658
Eliminated in respect of disposals
-
0
-
0
-
0
(37,081)
(37,081)
At 30 June 2025
20,294
52,844
1,306
31,643
106,087
Carrying amount
At 30 June 2025
80,233
6,475
76
51,461
138,245
At 30 June 2024
82,244
5,976
537
86,020
174,777
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
241,145
233,391
Corporation tax recoverable
635
635
Amounts owed by group undertakings
915,531
928,565
Other debtors
37,269
29,573
Prepayments and accrued income
154,012
3,298
1,348,592
1,195,462
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
1,881
1,695
Obligations under finance leases
9,766
13,037
Trade creditors
136,143
140,710
Corporation tax
70,923
16,966
Other taxation and social security
2,597
619
Other creditors
152,049
150,832
Accruals and deferred income
73,935
77,589
447,294
401,448
PARKSIDE PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
7
Creditors: amounts falling due within one year
(Continued)
- 8 -

Bank loans of £1,881 (2024: £1,695) are secured by way of a fixed and floating charge over all assets of the company.

8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
46,295
48,363
Other creditors
45,913
82,685
92,208
131,048

Bank loans of £46,295 (2024: £48,363) are secured by way of a fixed and floating charge over all assets of the company.

9
Related party transactions

The company is under the ultimate control of Mr S Nair, as he owns the majority share in Parkside Pharmacare Limited.

At 30 June 2025, Loan amounts of £571,238 (2024: £571,238) were due to Parkside Pharmacare Limited.

These loans are interest free and repayable on demand.

10
Parent company

The company is 100% owned by Parkside Pharmacare Limited, a company incorporated in England. The company registration number 09110273, the registered office of which is located at Front Street, Bellingham, Northumberland, NE48 2AA.

2025-06-30 2024-07-01 false false false 29 January 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr S Nair Mrs S Nair 04771472 2024-07-01 2025-06-30 04771472 2025-06-30 04771472 2024-06-30 04771472 core:NetGoodwill 2025-06-30 04771472 core:NetGoodwill 2024-06-30 04771472 core:LandBuildings core:OwnedOrFreeholdAssets 2025-06-30 04771472 core:PlantMachinery 2025-06-30 04771472 core:ComputerEquipment 2025-06-30 04771472 core:MotorVehicles 2025-06-30 04771472 core:LandBuildings core:OwnedOrFreeholdAssets 2024-06-30 04771472 core:PlantMachinery 2024-06-30 04771472 core:ComputerEquipment 2024-06-30 04771472 core:MotorVehicles 2024-06-30 04771472 core:CurrentFinancialInstruments 2025-06-30 04771472 core:CurrentFinancialInstruments 2024-06-30 04771472 core:Non-currentFinancialInstruments 2025-06-30 04771472 core:Non-currentFinancialInstruments 2024-06-30 04771472 core:ShareCapital 2025-06-30 04771472 core:ShareCapital 2024-06-30 04771472 core:RetainedEarningsAccumulatedLosses 2025-06-30 04771472 core:RetainedEarningsAccumulatedLosses 2024-06-30 04771472 bus:Director1 2024-07-01 2025-06-30 04771472 core:Goodwill 2024-07-01 2025-06-30 04771472 core:LandBuildings core:OwnedOrFreeholdAssets 2024-07-01 2025-06-30 04771472 core:PlantMachinery 2024-07-01 2025-06-30 04771472 core:ComputerEquipment 2024-07-01 2025-06-30 04771472 core:MotorVehicles 2024-07-01 2025-06-30 04771472 2023-07-01 2024-06-30 04771472 core:NetGoodwill 2024-06-30 04771472 core:LandBuildings core:OwnedOrFreeholdAssets 2024-06-30 04771472 core:PlantMachinery 2024-06-30 04771472 core:ComputerEquipment 2024-06-30 04771472 core:MotorVehicles 2024-06-30 04771472 2024-06-30 04771472 bus:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 04771472 bus:SmallCompaniesRegimeForAccounts 2024-07-01 2025-06-30 04771472 bus:FRS102 2024-07-01 2025-06-30 04771472 bus:AuditExemptWithAccountantsReport 2024-07-01 2025-06-30 04771472 bus:Director2 2024-07-01 2025-06-30 04771472 bus:FullAccounts 2024-07-01 2025-06-30 xbrli:pure xbrli:shares iso4217:GBP